Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MVA-NP+M1 Co-administered with Viroflu
NCT02014168Phase 1Terminated
- Sponsor
- University of Oxford
- Start
- Jan 2014
- Primary completion
- Apr 2014
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in influenza comparing Viroflu® and MVA-NP+M1 with Viroflu® and saline placebo (2 arms). Primary endpoints: Cellular immune response generated by co-administration of MVA-NP+M1 and the Viroflu® seasonal influenza vaccine at 26 weeks and Humoral immune response generated by co-administration of MVA-NP+M1 and the Viroflu® seasonal influenza vaccine at 26 weeks. Started Jan 2014; status: terminated.
02
Drugs
VTP-100
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02014168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014168.